Alik Farber, MD
Interim Chief and Chair
Boston University Chobanian & Avedisian School of Medicine
Radiology

MD, Harvard Medical School
BS, Brown University



Alik Farber, MD, MBA, is interim Chair of the Department of Surgery and Professor of Surgery and Radiology at the Boston University Chobanian & Avedisian School of Medicine. Dr. Farber is also interim Chief of the Department of Surgery at Boston Medical Center, where he is Associate Chief Medical Officer for Surgical Services and Chief of the Division of Vascular & Endovascular Surgery.

After earning his undergraduate degree from Brown University, Dr. Farber received his medical degree from Harvard Medical School. He completed residency in general surgery at Massachusetts General Hospital, a vascular surgery fellowship at Dartmouth-Hitchcock Medical Center, and an endovascular surgery fellowship at Southern Illinois School of Medicine. He received an MBA from the Heller School for Social Policy and Management at Brandeis University.

Dr. Farber began his career in 1999 as a vascular surgeon in private practice at Cedars-Sinai Medical Center in Los Angeles. In 2005, he was recruited to Boston Medical Center as an attending vascular surgeon and joined the faculty of the Chobanian & Avedisian School of Medicine as an Assistant Professor, rising to full Professor in 2015. Throughout his tenure, Dr. Farber has been involved in diverse academic, clinical operational, and leadership roles.

Dr. Farber’s clinical practice focuses on peripheral artery disease. An internationally recognized authority on limb ischemia, he has been invited to contribute to multidisciplinary consensus statements and has lectured across the world on this topic. Dr. Farber has served as principal investigator (PI) for multiple clinical trials involving wound care, intermittent claudication, and deep-vein arterialization. Most recently he served as co-PI of the landmark Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial. Funded by the National Heart, Lung, and Blood Institute, this international, multicenter, randomized controlled trial compared traditional bypass surgery with endovascular treatment for patients with chronic limb threatening ischemia. More than 1,800 patients at 150 sites across North America, Europe, and New Zealand were enrolled, with results published in The New England Journal of Medicine in 2022. Dr. Farber, who chairs the BEST-CLI Publications Committee, continues to be actively involved in trial dataset analysis and research dissemination through the BEST-CLI Collaborative, funded by the Novo Nordisk Foundation.

A fellow of the American College of Surgeons and a distinguished fellow of the Society of Vascular Surgery, Dr. Farber frequently serves in leadership roles for professional organizations. Currently, he is Secretary of the Society for Clinical Vascular Surgery and Treasurer of both the New England Society for Vascular Surgery and the Massachusetts Chapter of the American College of Surgeons.

Dr. Farber has authored more than 260 peer-reviewed manuscripts and 30 book chapters, and has edited two textbooks. He has given more than 160 presentations in over 20 countries.

Professor
Boston University Chobanian & Avedisian School of Medicine
Surgery
Vascular and Endovascular Surgery

Associate Chief Medical Officer for Surgical Services
Boston Medical Center


Section Chief
Boston University Chobanian & Avedisian School of Medicine
Surgery
Vascular and Endovascular Surgery

Professor
Boston University Chobanian & Avedisian School of Medicine
Radiology
Vascular & Interventional

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols
05/01/2012 - 12/31/2015 (PI)
Grifols Inc.


A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm^2 to <= 36 cm^2
10/15/2013 - 08/30/2015 (PI)
HealthPoint Limited


A Non-Interventional Safety Study Providing 12 Months Follow-Up from First Exposure to HP802-247 in Subjects with Venous Leg Ulcer
05/01/2012 - 04/30/2015 (PI)
HealthPoint Limited


Observational Study of Tissue Plasminogen Activator Used for Catheter Directed Thrombolysis in Patients with Acute Lower Extremety Native Artery or Bypass Graft Occlusion
01/27/2014 - 01/26/2015 (PI)
Grifols Inc.


A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
05/01/2012 - 04/30/2014 (PI)
HealthPoint Limited


Vital Access Venous Window Needle Guide for salvage of AV Fistulae (SAVE) Trial
08/15/2012 - 08/14/2013 (PI)
Vital Access Corp


IN-BALANCE VLU (Inflammation, Bacteria, and Angiogenesis effects in launching venous leg ulcer healing: a clinical evaluation)
08/01/2012 - 07/31/2013 (PI)
Celleration, Inc.


A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals


A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals


A Phase II Randomized, Double Blind, Placebo Controlled Dose Finding Study Investigating the Efficacy of HP802-247 in Venous Leg Ulcers
08/01/2009 - 12/31/2011 (PI)
HealthPoint Limited


Showing 10 of 16 results. Show All Results

LF-CA-PR-53-PROMISE III Trial
12/09/2022 - 12/09/2025 (PI)
LimFlow Inc

Assessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treating Diabetic Foot Ulcers (DFU) and with Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)
10/12/2022 - 10/12/2025 (PI)
Acera Surgical Inc.

Novonordisk-NN9535-4533
09/14/2021 - 09/14/2024 (PI)
Novo Nordisk

Natural Progression of High-Risk Chronic Limb-Threatening Ischemia. The CLariTI Study.
03/25/2021 - 03/25/2024 (PI)
LimFlow Inc

A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dressing on subjects with lower extremity venous ulcerss
10/14/2020 - 10/14/2023 (PI)
Medline Industries LLC

Pre notification BEST-CLI Data Analysis and Publications Core
09/01/2022 - 08/31/2023 (PI)
Brigham and Womens Hospital Novo Nordisk Foundat

A multicenter retrospective observational study to evaluate primary patency of arteriovenous fistulae 6 months post-surgery.
11/23/2020 - 04/30/2023 (PI)
Laminate Medical Technologies Inc.

BEST-CLI Trial-CCC-Lead
09/17/2013 - 03/31/2023 (PI)
Brigham and Womens Hospital National Heart, Lung
1U01HL107352-01A1

A Pivotal Study to Investigate the Safety and Effectiveness of the Limflow System for the…
12/11/2019 - 12/11/2022 (PI)
LimFlow Inc

A multi-center prospective study to evaluate the safety and effectiveness of the VasQ external suppo
11/01/2017 - 11/01/2022 (PI)
Laminate Medical Technologies Inc.

Showing 10 of 19 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Menard MT, Farber A, Powell RJ, Rosenfield K, Conte MS, Hamza TH, Kaufman JA, Cziraky MJ, Creager MA, Dake MD, Jaff MR, Reid D, Sopko G, White CJ, Strong MB, van Over M, Chisci E, Goodney PP, Gray B, Kayssi A, Siracuse JJ, Choudhry NK. Quality of Life in Patients With Chronic Limb-Threatening Ischemia Treated With Revascularization. Circulation. 2024 Apr 16; 149(16):1241-1253.View Related Profiles. PMID: 38597097
     
  2. D'Angelo O, Menard MT, Farber A. Common Criticisms and Rebuttals of the Best Endovascular Versus Best Surgical Therapy in Patients with Chronic Limb-Threatening Ischemia (BEST-CLI) Trial. Ann Vasc Surg. 2024 Apr 08. PMID: 38599479
     
  3. Patrone L, Pasqui E, Conte MS, Farber A, Ferraresi R, Menard M, Mills JL, Rundback J, Schneider P, Ysa A, Abhishek K, Adams GL, Ahmad N, Ahmed I, Alexandrescu VA, Amor M, Alper D, Andrassy M, Attinger C, Baadh A, Barakat H, Biasi L, Bisdas T, Bhatti Z, Blessing E, Bonaca MP, Bonvini S, Bosiers M, Bradbury AW, Beasley R, Behrendt CA, Brodmann M, Cabral G, Cancellieri R, Casini A, Chandra V, Chisci E, Chohan O, Choke ETC, Chong PFS, Clerici G, Coscas R, Costantino M, Dalla Paola L, Dand S, Davies RSM, D'Oria M, Diamantopoulos A, Debus S, Deloose K, Del Giudice C, Donato G, Rubertis B, Paul De Vries J, Dias NV, Diaz-Sandoval L, Dick F, Donas K, Dua A, Fanelli F, Fazzini S, Foteh M, Gandini R, Gargiulo M, Garriboli L, Genovese EA, Gifford E, Goueffic Y, Goverde P, Chand Gupta P, Hinchliffe R, Holden A, Houlind KC, Howard DP, Huasen B, Isernia G, Katsanos K, Katzen B, Kolh P, Koncar I, Korosoglou G, Krishnan P, Kroencke T, Krokidis M, Kumarasamy A, Hayes P, Iida O, Alejandre Lafont E, Langhoff R, Lecis A, Lessne M, Lichaa H, Lichtenberg M, Lobato M, Lopes A, Loreni G, Lucatelli P, Madassery S, Maene L, Manzi M, Maresch M, Santhosh Mathews J, McCaslin J, Micari A, Michelagnoli S, Migliara B, Morgan R, Morelli L, Morosetti D, Mouawad N, Moxey P, Müller-Hülsbeck S, Mustapha J, Nakama T, Nasr B, N'dandu Z, Neville R, Noory E, Nordanstig J, Noronen K, Mariano Palena L, Parlani G, Patel AS, Patel P, Patel R, Patel S, Pena C, Perkov D, Portou M, Pratesi G, Rammos C, Reekers J, Riambau V, Roy T, Rosenfield K, Antonella Ruffino M, Saab F, Saratzis A, Sbarzaglia P, Schmidt A, Secemsky E, Siah M, Sillesen H, Simonte G, Sirvent M, Sommerset J, Steiner S, Sakr A, Scheinert D, Shishebor M, Spiliopoulos S, Spinelli A, Stravoulakis K, Taneva G, Teso D, Tessarek J, Theivacumar S, Thomas A, Thomas S, Thulasidasan N, Torsello G, Tripathi R, Troisi N, Tummala S, Tummala V, Twine C, Uberoi R, Ucci A, Valenti D, van den Berg J, van den Heuvel D, Van Herzeele I, Varcoe R, Vega de Ceniga M, Veith FJ, Venermo M, Vijaynagar B, Virdee S, Von Stempel C, Voûte MT, Khee Yeung K, Zeller T, Zayed H, Montero Baker M. The "Woundosome" Concept and Its Impact on Procedural Outcomes in Patients With Chronic Limb-Threatening Ischemia. J Endovasc Ther. 2024 Mar 25; 15266028241231745. PMID: 38523459
     
  4. Conte MS, Azene E, Doros G, Gasper WJ, Hamza T, Kashyap VS, Guzman R, Mena-Hurtado C, Menard MT, Rosenfield K, Rowe VL, Strong M, Farber A. Secondary interventions following open vs endovascular revascularization for chronic limb threatening ischemia in the BEST-CLI trial. J Vasc Surg. 2024 Feb 17.View Related Profiles. PMID: 38368997
     
  5. Nwachuku EC, Farber A. Open Surgical Therapy for Peripheral Artery Disease. Curr Cardiol Rep. 2024 Apr; 26(4):211-220. PMID: 38342801
     
  6. Kobzeva-Herzog AJ, Levin SR, Young S, McNamara TE, Alonso AG, Farber A, King EG, Siracuse JJ. Assessing Time to Removal of Tunneled Dialysis Catheters after Arteriovenous Access Creation. Ann Vasc Surg. 2024 May; 102:35-41.View Related Profiles. PMID: 38377711
     
  7. Farber A, Menard MT, Bonaca MP, Bradbury A, Conte MS, Debus ES, Eldrup N, Goodney P, Gupta PC, Hinchliffe RJ, Houlind KC, Kolh P, Kum SWC, Nordanstig J, Parikh SA, Patel MR, Patrone L, Sillesen H, Strong MB, Varcoe RL, Vega de Ceniga M, Venermo MA, Rosenfield K. BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally. Br J Surg. 2024 Jan 31; 111(2). PMID: 38294083; PMCID: PMC10828928; DOI: 10.1093/bjs/znad413;
     
  8. Forsyth A, Haqqani MH, Alfson DB, Shaikh SP, Brea F, Richman A, Siracuse JJ, Rybin D, Farber A, Brahmbhatt TS. Long-term outcomes of autologous vein bypass for repair of upper and lower extremity major arterial trauma. J Vasc Surg. 2024 Jan 30.View Related Profiles. PMID: 38301809
     
  9. Smeds MR, Cheng TW, King E, Williams M, Farber A, Chitalia VC, Siracuse JJ. Characterization of long-term survival in Medicare patients undergoing arteriovenous hemodialysis access. J Vasc Surg. 2024 Apr; 79(4):925-930.View Related Profiles. PMID: 38237702
     
  10. Zhu M, Arinze N, Buitron de la Vega P, Alonso A, Levin S, Farber A, King E, Kobzeva-Herzog A, Chitalia VC, Siracuse JJ. High Prevalence of Adverse Social Determinants of Health in Dialysis Access Creation Patients in a Safety-Net Setting. Ann Vasc Surg. 2024 Mar; 100:31-38.View Related Profiles. PMID: 38110081
     
Showing 10 of 354 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 351 publications over 26 distinct years, with a maximum of 41 publications in 2016

YearPublications
19921
19931
19992
20011
20022
20033
20044
20051
20073
20082
20096
20104
201112
20129
201319
201415
201521
201641
201738
201840
201925
202036
202119
202214
202323
20249

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
Contact for Mentoring:

75 E. Newton St Collamore Building
Boston MA 02118
Google Map


Farber's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department